Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.
Andreas KronbichlerJulia KerschbaumSeerapani GopaluniJoanna TieuFederico AlbericiRachel Bronwen JonesRona M SmithDavid R W JaynePublished in: Annals of the rheumatic diseases (2018)
We found severe infections in one quarter of patients with AAV receiving rituximab. Trimethoprim-sulfamethoxazole prophylaxis reduced the risk, while especially bronchiectasis and endobronchial involvement are risk factors for severe respiratory infections.